Meridian Bioscience Management
Management criteria checks 3/4
Meridian Bioscience's CEO is Jack Kenny, appointed in Oct 2017, has a tenure of 5.33 years. total yearly compensation is $4.60M, comprised of 15.4% salary and 84.6% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $4.17M. The average tenure of the management team and the board of directors is 3.6 years and 6.8 years respectively.
Key information
Jack Kenny
Chief executive officer
US$4.6m
Total compensation
| CEO salary percentage | 15.4% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.6yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27
Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09
Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | US$5m | US$710k | US$42m |
| Jun 30 2022 | n/a | n/a | US$43m |
| Mar 31 2022 | n/a | n/a | US$62m |
| Dec 31 2021 | n/a | n/a | US$60m |
| Sep 30 2021 | US$3m | US$690k | US$71m |
| Jun 30 2021 | n/a | n/a | US$71m |
| Mar 31 2021 | n/a | n/a | US$87m |
| Dec 31 2020 | n/a | n/a | US$70m |
| Sep 30 2020 | US$3m | US$670k | US$46m |
| Jun 30 2020 | n/a | n/a | US$44m |
| Mar 31 2020 | n/a | n/a | US$21m |
| Dec 31 2019 | n/a | n/a | US$19m |
| Sep 30 2019 | US$1m | US$650k | US$24m |
| Jun 30 2019 | n/a | n/a | US$26m |
| Mar 31 2019 | n/a | n/a | US$27m |
| Dec 31 2018 | n/a | n/a | US$26m |
| Sep 30 2018 | US$2m | US$542k | US$24m |
Compensation vs Market: Jack's total compensation ($USD4.60M) is about average for companies of similar size in the US market ($USD5.11M).
Compensation vs Earnings: Jack's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Jack Kenny (53 yo)
5.3yrs
Tenure
US$4,598,825
Compensation
Mr. John P. Kenny, also known as Jack, has been the Chief Executive Officer of Meridian Bioscience, Inc. since October 9, 2017. Mr. Kenny serves as President of Meridian Bioscience, Inc. and served as its...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.3yrs | US$4.60m | 0.28% $ 4.2m | |
| Executive VP & CFO | less than a year | US$1.03m | 0.0092% $ 137.4k | |
| Senior VP | 1.2yrs | US$786.42k | 0.097% $ 1.5m | |
| Executive Vice President of Life Science Business Unit | 9.4yrs | US$1.23m | 0.13% $ 2.0m | |
| Executive Vice President of Diagnostics | 2.8yrs | US$1.20m | 0.038% $ 567.0k | |
| Director of Corporate Finance | no data | no data | no data | |
| Vice President of Corporate Strategy | 3.1yrs | no data | no data | |
| Senior VP & General Counsel | less than a year | no data | no data | |
| Vice President of Global Human Resources | 4.8yrs | no data | no data | |
| Consultant | 4.3yrs | US$626.75k | no data | |
| Consultant | 4.1yrs | US$432.97k | no data |
3.6yrs
Average Tenure
57yo
Average Age
Experienced Management: VIVO's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$4.60m | 0.28% $ 4.2m | |
| Independent Director | 5.5yrs | US$176.25k | 0.056% $ 833.6k | |
| Chairman | 7.5yrs | US$212.75k | 0.043% $ 638.2k | |
| Independent Director | 13.6yrs | US$197.00k | 0.069% $ 1.0m | |
| Independent Director | 4.4yrs | US$192.50k | 0.017% $ 247.7k | |
| Independent Director | 2.6yrs | US$189.63k | 0.028% $ 422.8k | |
| Independent Director | 8.6yrs | US$177.50k | 0.033% $ 487.1k | |
| Independent Director | 7.5yrs | US$191.13k | 0.031% $ 457.5k |
6.8yrs
Average Tenure
66yo
Average Age
Experienced Board: VIVO's board of directors are considered experienced (6.8 years average tenure).